INTRODUCTION
Accumulating evidence support the notion that multiple sclerosis (MS) is primarily an autoimmune disease, characterized by lesions in the brain and spinal cord caused by demyelination as a result of periodical infiltration of autoreactive immune cells. This leads to a progressive accumulation of sclerotic plaques where nerve axons are damaged, in turn leading to increasing neurological disability. Typically, the disease starts in early adulthood and is more common in women. 1 The human leukocyte antigen (HLA) region on chromosome 6 has been established as the main genetic risk determinant area for MS, with the strongest disease-promoting effect exerted by class II DRB1*15:01, 2, 3 whereas the class I A*02 allele has been associated with reduced risk. 4, 5 However, the disease etiology of MS is complex and several other genes as well as environmental factors provide additional influences on disease risk. 4, 6 The CIITA gene (16p13) is of particular interest as a candidate gene for several autoimmune diseases, as the encoded protein functions as an assembler of the transcription factors necessary for transcription of major histocompability complex class II (MHCII) molecules. The essential function of CIITA is evident in Bare Lymphocyte Syndrome, a rare condition characterized by lack of MHCII molecules associated with severe immunodeficiency 7 (Online Mendelian Inheritance in Man (OMIM) 9920). In addition, CIITA may also be involved in the regulation of expression of class I molecules as well as other genes in immune cells. 8, 9 The CIITA gene is controlled by four independent and cell type-specific promoters (PI-PIV), and the gene product expressed from promotor III is the one mostly investigated, as it is used in B cells, activated T cells and plasmacytoid dendritic cells. The promotor I (PI) mainly controls CIITA expression in myeloid dendritic cells and macrophages. Promotor IV is used in a variety of cells, among them thymic epthelial cells, whereas the promoter II (PII) is of unknown function in humans. 10 Variability in the CIITA gene has been reported to be associated with several diseases such as MS, 11 myocardial infarction (MI) 11 rheumatoid arthritis (RA), 11, 12 type 1 diabetes (T1D), 13 Addison's disease 14 and celiac disease, 15 but lack of association has also been reported in several studies, [16] [17] [18] and association has not always been possible to reproduce in different populations. We have recently shown that the allele frequency of CIITA markers vary with age in a large pooled material of individuals used as controls in different genetic association studies. 13 It is therefore possible that contradictory findings regarding any possible association between CIITA and disease risk at least in part can be explained by insufficient matching for age between patients and controls.
Various single-nucleotide polymorphisms (SNPs) in the CIITA gene have been associated with MS risk. Thus, Swanberg et al.
11
reported association with rs3087456 and also decreased 1 expression of MHCII transcripts after stimulation of leukocytes with interferon-g for the minor allele of rs3087456. Bronson et al. 19 found association with MS for marker rs4774, particularly in DRB1*15:01-positive individuals, but could not reproduce the finding of the rs3087456 SNP.
In this study we investigate the possible association of several SNPs in the CIITA gene to MS, among them the earlier reported rs4774 and rs3087456, as well as the interaction with DRB1*15 and A*02, taking care to correct for variation in age.
We test the association both in the whole cohort of cases and controls, and after stratification for DRB1*15 and A*02.
We initially found association for rs4774, which was stronger when stratifying for the presence of DRB1*15 and A*02, respectively. In addition, interactions between the CIITA marker and HLA alleles on both the multiplicative and the additive scales were detected.
RESULTS
SNP markers in the CIITA gene were selected based on prior reports of association with MS (rs3087456, rs4774) and our previous study of CIITA in T1D. 13 First, we performed an univariate association analysis between CIITA markers and MS in the combined material of 2000 MS patients and up to 6900 controls from studies of MS, RA, MI and T1D (Supplementary Table 1 ), based on presence of minor allele versus major allele homozygotes. A significant association of rs4774 (P ¼ 0.01) was discovered in this analysis (Table 1) .
We have previously shown that the frequency of genotypes within the CIITA gene varies with age among controls, and therefore matching for age among cases and controls should be considered in association studies. 13 In a logistic regression model with age as a covariate, the association with MS remained for rs4774 (P ¼ 0.01, odds ratio (OR) 1.17, 95% confidence interval CI: 1.03-1.31; Table 1 ). None of the other CIITA markers were associated with MS in any of these analyses.
Bronson et al. 19 found a stronger association with MS for the rs4774 marker with stratification for presence of the main diseaseassociated class II haplotype DRB1*15:01. We therefore investigated association of rs4774 when all individuals were stratified for HLA-DRB1*15, and also when all individuals were stratified for HLA-A*02, and corrected for age with logistic regression.
In the DRB1*15-positive cohort (977 cases, 932 controls), association for rs4774 (P ¼ 0.03, OR: 1.23, 95% CI: 1.02-1.49) was observed (Table 2 ), but we also detected a suggestive association with MS for rs3087456 minor allele homozygotes (1011 cases and 1154 controls, P ¼ 0.07; data not shown). None of the other investigated CIITA SNPs were associated among DRB1*15 stratified individuals. We also investigated whether there was any association between SNPs in CIITA and DRB1*15 among the controls, but found no such association (data not shown).
When the material was stratified in the same manner for the absence of DRB1*15, no association was found between CIITA and MS among DRB1*15-negative individuals ( Table 2) .
The same analysis was performed in cohorts stratified for the presence or absence of HLA-A*02. We here found that rs4774 was associated with MS in cases stratified for HLA-A*02 (650 cases, 757 controls, P ¼ 0.01, OR: 1.33, 95% CI: 1.07-1.64), but not in the absence of HLA-A*02 (Table 2) . No other marker showed significant association in these cohorts. We also found association Genetic HLA-CIITA interactions in MS A Gyllenberg et al between A*02 and rs4774 among the controls, with homozygotes for the minor allele being more common among those who lack A*02 (P ¼ 0.02). When we investigated the interaction between HLA and CIITA, we detected multiplicative interaction for rs4774-A*02 (P ¼ 0.03, OR: 1.40, 95% CI: 1.02-1.90) and additive interaction for rs4774-DRB1*15 (attributable proportion: 0.17, 95% CI: 0.01-0.33, P ¼ 0.04; Figure 1 ). The detected interaction suggests that for individuals who carry the DRB1*15 haplotype, the minor allele of rs4774 exerts an increased risk.
Four markers in the nearby CLEC16A gene, an established MS risk gene, 20, 21 were included in the analyses to rule out that any association in CIITA was because of linkage disequilibrium (LD) with this gene. The SNPs have been reported in genome-wide association studies 20, 22 and lately in the MS Immunochip study 23 as the strongest associated markers to MS in the CLEC16A gene. In our material, all of the four CLEC16A markers were significantly associated with MS (Table 1) , and the association with rs4774 remained significant (Po0.05) when adding them to the logistic regression model. We also performed an LD plot ( Figure 2 ) demonstrating a low LD between the markers in the two genes (r 2 p0.04).
Finally, we conducted a meta-analysis on the material presented here and that of Bronson et al. with stratification of cases for the presence of DRB1*15 ( Figure 3 ). In this analysis, the association found by us is weaker than the association that Bronson et al. 19 found in their cohorts, but goes in the same direction and the combined OR is 1.3 (95% CI: 1.15-1.42) for the presence of the minor allele (CC, CG) versus major allele homozygotes (GG).
DISCUSSION
We here replicate the previous findings 11, 19 of an association between genetic variability in CIITA and MS risk. Based on the biological function, the CIITA gene is a particularly interesting candidate gene in autoimmune diseases, considering its crucial role in regulating the expression of MHCII molecules, in turn the main genetic determinant of disease risk. The MHCII molecules are central in antigen presentation to lymphocytes, and also for presenting self-proteins and contributing to maintaining immunological tolerance. The DRB1 locus in the HLA class II region is the major established genetic determinant of disease risk in MS that makes interaction between these loci plausible for any possible association with the CIITA gene. Experimental studies also suggest that CIITA is involved in the regulation of MHCI genes, as well as other immune genes, making additional associations possible. 9, 24 In previous studies, variability in the CIITA gene have been reported to be associated with several autoimmune diseases. However, negative studies failing to replicate these results have also been published. [16] [17] [18] These contradictory findings may depend on heterogeneity in case-ontrol studies, technical issues and on how the control groups were chosen. We have recently shown that there is a variation in allele frequencies for markers in CIITA depending on age among a large pooled cohort of controls used in genetic association studies. 13 Thus, lack of age matching between cases and controls may affect the results in association studies. The earlier reported rs3087456 marker in CIITA is one such marker on which there has been a controversy and contradictive results in different studies. In the current study we could not find any association with this marker in the present cohort. However, when we stratified both cases and controls for DRB1*15 and corrected for age in logistic regression, we detected a tendency toward association with MS for the minor allele homozygote for this marker (P ¼ 0.07, data not shown). In addition, the initial association of rs4774 with MS in the univariate analysis was strengthened when we stratified cases for DRB1*15 or A*02 Figure 1 . Additive interaction between HLA and rs4774. Presence of HLA-DRB1*15 together with the presence of minor allele (CG, CC) for rs4774 increases the OR for MS. Error bars are 95% CI of OR estimates. Attributable proportion (AP) due to interaction is the proportion of the incidence among individuals exposed to both associated factors compared with the factors individually. The AP value is significant if separated from zero. HLA is coded as the presence of one or two alleles for HLA-DRB1*15, and rs4774 was coded as the presence of minor allele (CG, CC). Genetic HLA-CIITA interactions in MS A Gyllenberg et al haplotype. Earlier studies (except Bronson et al. 19 ) have not taken into account the effect of HLA haplotypes in the investigated material, and this likely has an influence on the results given the biological function of CIITA.
CLEC16A is a well-established risk gene for MS that maps close to the CIITA gene. 20, 21 It has been shown that the association with MS for these two genes are independent of each other, 19 and the relationship between CIITA and CLEC16A has been investigated thoroughly, revealing a low degree of LD between the genes, 25 which is also confirmed in our material (r 2 p0.04; Figure 2 ). The significance level of the observed association for rs4774 with MS in our material is modest and does not reach genomewide significance. No SNPs in CIITA have been reported as associated with MS in genome-wide studies. However, given the complex nature of the etiology of MS, genes with low or moderate effect are believed to affect the disease as well. When we performed a meta analysis with our data and that of Bronson et al., 19 the effect was in the same direction, which supports a role for CIITA in MS susceptibility.
When performing genetic association studies it is important to consider the effect of population stratification. In this study we do not have genome-wide SNP genotypes for all our samples that would have allowed us to perform principal component analysis. Instead, we have removed all individuals with known nonScandinavian descent, and when principal component analysis was possible we have removed outliers. It should also be pointed out that all individuals are residents in Sweden and collected from Swedish clinics, which should increase the ethnic homogeneity.
The physical relevance of the association of this CIITA marker depending on DRB1*15 and A*02 is unknown; possibly, it could have effect on the function of the CIITA gene and subsequently on MHCI and II expression that in turn have different outcomes depending on what HLA allele an individual carries. Swanberg et al. 11 found a lower expression of the CIITA gene and lower levels of MHCII transcripts for individuals with the minor allele homozygote (GG) genotype of CIITA marker rs3087456 in stimulated peripheral blood mononucleated cells as compared with other genotypes. The LD between rs3087456 and rs4774 is low, and hence we cannot conclude that rs4774 affects expression of MHCII from this study. The rs4774 is not situated in a promotor region but is a missense mutation, causing amino acid change from glycine to alanine. How this will affect the expression of the CIITA gene and the function of the CIITA protein remains unclear. Further experiments are needed to test this hypothesis.
It can be argued that variability in expression of the strongly associated HLA haplotype DRB1*15 could have an effect on MS susceptibility, whereas variation in the expression of HLA haplotypes not associated with MS does not affect MS susceptibility.
The MHCII molecule is important for both T-cell selection in the thymus and antigen recognition in the periphery. A variation in MHCII expression could affect disease susceptibility by several mechanisms, for example through lack of tolerance induction in T cells, influenced effect on regulatory T cells or less effective clearing of pathogens that could play a role in disease onset. 26 The MHCI molecules are mainly involved in presenting intracellular pathogens, such as viruses. Indeed, there is now evidence that certain viruses, for example Epstein-Barr virus, modify MS disease risk. 27, 28 In contrast, infection with cytomegalovirus may result in a lowered MS risk. 29, 30 It is also possible that different HLA class I alleles influence the immune response depending on the efficiency of clearance of infection of MS-associated viruses or by inducing tolerance in autoreactive Tcells. 5 Further efforts directed at replicating the current findings and dissecting the mechanistic basis for how the polymorphisms studied affect CIITA function, and subsequently autoimmune responses, are needed to clarify the role of genetic variability in the CIITA gene.
MATERIALS AND METHODS

Ethics statement
All included patient and control materials and analyses in this study were approved by the Regional Ethical Review Boards in the cities of Stockholm, Lund and Umeå in Sweden (www.epn.se). Informed consent from all study participants or their parents was obtained. Investigations were carried out according to the guidelines from the Declaration of Helsinki.
Subjects: MS patients and controls
The MS patients were collected from the study cohorts described below. In total, there were 2003 Swedish MS patients and 1672 controls (not all patients or controls were typed for all markers, see Supplementary Table 1 ). All MS cases have been diagnosed either according to McDonald's criteria 31 or Poser's criteria, 32 and individuals of known non-Scandinavian origin were excluded from the current study.
The Epidemiological Investigation of Multiple Sclerosis (EIMS).
A population based nation-wide case-control cohort with incident cases of MS that has been described previously. 33 The controls were randomly selected from the national population register and matched to the case's sex, age and residential area; 625 cases and 475 controls from this group were used in the current study.
The Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) cohort.
The cohort consists exclusively of cases (n ¼ 318) with relapsing-remitting MS from clinics throughout Sweden who were being treated with natalizumab. 34 The Stockholm Multiple Sclerosis cohort (STOP MS). The patients fulfilled the McDonald criteria 31 for definite MS and were recruited by neurologists at the Karolinska University Hospital Huddinge and Solna sites in Stockholm, Sweden. The patients in the cohort were between 22 and 91 years of age and the controls were matched for ethnicity and constitutes of blood donors between 21 and 76 years of age. A total of 1060 cases and 1197 controls were used from this group. All patients and controls were originating from Sweden or other Nordic countries. 35 
Extra controls
To further increase the power of the analyses, extra control cohorts were included from previous studies of RA, T1D and MI (not all controls were typed for all markers, see Supplementary Table 1) .
Rheumatoid arthritis. A total of 1426 healthy controls were matched to RA patients by age, sex and residential area. The recruitment of affected individuals and controls has been described previously in connection with EIRA study. 36 Of the study population, 97% was of self-reported Caucasian origin. No chronic diseases were reported among these controls. Individuals deviating in a principal component analysis or of known nonScandinavian origin were excluded from the current study. Type 1 diabetes: Swedish Childhood Study (SV2). From the Swedish Childhood registry during 1986 and 1987, 476 controls to T1D patients were selected. The controls were geographically, gender and age matched to all cases of T1D in the cohort above 7 years of age (n ¼ 423). For patients under the age of 7 years, a control was selected among patients being treated at the hospital for reasons other than T1D (n ¼ 53). 40 Type 1 diabetes: Diabetes Registry in Southern Sweden (DR). In total, 2312 healthy controls from this study were included, 1695 men and 617 women, between 45 and 75 years of age. 41 Individuals of known non-Scandinavian origin were excluded (n ¼ 100).
Genetic HLA-CIITA interactions in MS A Gyllenberg et al Myocardial infarction: SCARF. From the SCARF 42 study of MI, the control group consists of 387 healthy individuals between 40 and 60 years of age, sex and age matched for the MI cases and recruited from the general population, and of self-reported Caucasian origin.
In this study, there is a partial overlap of cases and controls with a previously published MS study 11 for the Stockholm MS cohort (548 cases, 528 controls), the RA cohort (709 controls) and the MI cohort (387 controls). All individuals with known non-Scandinavian descent have been removed from this study.
Genotyping methods
For MS patients and controls, all SNPs were genotyped with the allelic discrimination method for TaqMan ABI 7900 (Applied Biosystems, Inc., ABI, Stockholm, Sweden) 43 except for markers rs3087456 and rs4774, where individuals in the Stockholm MS cohort included in our previous publication were genotyped with matrix-assisted laser desorption/ ionization-time-of-flight as described previously. 11 In the DISS2 cohort the TaqMan ABI 7900 typing method was used for all markers except for rs4774 and rs3087456 for which the dynamic allelespecific hybridization (DASH) method 44 was used. DISS1 and SV2 cohorts were genotyped using the MassArray chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (Sequenom Inc., San Diego, CA, USA) using the Homogeneous MassEXTEND chemistry as described previously. 45 Controls from the DR study were genotyped with the TaqMan ABI method as above.
In the RA and MI controls, rs3087456 were genotyped with 5 0 nuclease assays, and rs4774 with matrix-assisted laser desorption/ionization-time-offlight as described previously, 11 and remaining CIITA markers were genotyped with the TaqMan ABI method as above.
Additional genotypes for rs4774 (81 cases, 227 controls) for individuals already in the study but lacking genotypes for this marker were retrieved from the ImmunoChip custom genotyping array. 23 Genotyping methods for HLA DRB1*15 and A*02
The genotyping of DRB1*15 and A*02 in the MS cohorts, as well as the genotyping of DRB1*15 in RA and DISS2 cohorts, was performed by allelespecific amplification as described earlier. 46 In the DISS1 and SV2 cohorts, DRB1*15 was genotyped by restriction fragment-length polymorphism. 47 For individuals also included in the MS Immunochip study, 23 we used imputed genotypes for HLA where we lacked this information, adding information regarding HLA-A*02 for 145 individuals and for HLA-DRB1*15 for 128 individuals. The imputation was performed using HLA*IMP:0212, 48 based on SNPs genotyped on the Immunochip custom array. 49 The other cohorts have not been typed for HLA. In total, 1959 MS cases and 4407controls had data concerning HLA DRB1*15 status and 1905 cases and 1762 controls had data concerning A2 status.
All HLA genotyping was performed at two-digit level. HLA coding was defined as the presence or absence of allele for DRB1*15 and A*02.
Statistical analysis
Univariate association was tested using Pearson's w 2 test. Logistic regression analysis using generalized linear modeling was used in multivariate analysis when correcting for the effect of age on the CIITA association. Age group 8 (35-39 years) was used as a reference group in the multivariate analysis. Interaction on the multiplicative scale was tested using logistic regression including both variables (a, b) investigated, as well as the interaction variable (a Â b) and confounders (age).
To investigate additive interaction, departure from additivity was estimated by calculating attributable proportion due to interaction. The analysis was performed as described previously 50 using the generalized linear modeling (glm) in R and the vcov command to get the covariance matrix.
A meta-analysis was performed using fixed effect Mantel-Haenszel analysis and Woolf's test for heterogeneity in R using the meta.MH command in the rmeta package. No heterogeneity between groups was discovered.
All statistical analyses were performed in the statistical computer program R 2.14.1 (Vienna, Austria). 51 The LD structure plot (Figure 1 ) for investigated markers in the MS cohort was performed in Haploview 4.2.
